**Interim Clinical Considerations**

**for Use of COVID-19 Vaccines Currently Authorized in the United States**

<table>
<thead>
<tr>
<th>Vaccine type</th>
<th>Pfizer-BioNTech</th>
<th>Moderna</th>
<th>Janssen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authorized age groups</td>
<td>≥12 years</td>
<td>≥18 years</td>
<td>≥18 years</td>
</tr>
<tr>
<td>Dose volume</td>
<td>0.3 ml</td>
<td>0.5 ml</td>
<td>0.5 ml</td>
</tr>
<tr>
<td>Dose</td>
<td>30 µg</td>
<td>100 µg</td>
<td>5x10^10 viral particles</td>
</tr>
<tr>
<td>Number of doses in series</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Interval between doses</td>
<td>3 weeks (21 days)</td>
<td>1 month (28 days)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**All currently authorized COVID-19 vaccines**

- Vaccines are not interchangeable. However, in exceptional situations, such as a contraindication to a second dose of mRNA vaccine, interchangeability may be allowed.*

**Interchangeability of vaccines**

- COVID-19 vaccine and other vaccines may be administered on the same day, as well as any interval without respect to timing. When deciding whether to administer COVID-19 vaccine and other vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable diseases (e.g., during an outbreak), and the reactogenicity profile of the vaccines.

**Persons with prior or current COVID-19**

- COVID-19 vaccines can be given safely to people with prior SARS-CoV-2 infection
- Defer vaccination until person has recovered from the acute illness and criteria have been met for them to discontinue isolation

**Women aged <50 years**

- Can receive any FDA-authorized vaccine but should be informed of risk of thrombosis with thrombocytopenia syndrome (TTTS) after receipt of Janssen (Johnson & Johnson) COVID-19 Vaccine and the availability of other COVID-19 vaccine options

**Persons who received monoclonal antibodies or convalescent plasma for COVID-19 treatment**

- Defer vaccination for at least 90 days

**Persons with a known SARS-CoV-2 exposure**

- Persons in community or outpatient setting should defer vaccination until quarantine period has ended
- Residents or patients in congregate settings may be vaccinated if they do not have symptoms consistent with COVID-19

**History of heparin-induced thrombocytopenia (HIT)**

- If within 90 days of illness, offer an mRNA vaccine, after 90 days vaccinate with any FDA-authorized COVID-19 vaccine

**Persons with underlying conditions**

- May receive COVID-19 vaccine

**Persons with moderate to severe immune compromise**

- Can receive any FDA-authorized COVID-19 vaccine
  - 1 dose Janssen COVID-19 Vaccine; currently no recommendation for an additional dose, or
  - 2-doses of an mRNA COVID-19 vaccine; consider an additional dose at least 28 days after completion of the primary 2-dose series

**Persons with a history of Guillain-Barré Syndrome**

- Can receive any FDA-authorized COVID-19 vaccine, however, discuss the availability of mRNA vaccines to offer protection against COVID-19

**Pregnant or breastfeeding people or people trying to get pregnant**

- Are recommended to receive a COVID-19 vaccine, inform of risk of TTS after receipt of Janssen (Johnson & Johnson) COVID-19 Vaccine and the availability of other options

**Adolescents**

- Adolescents aged 12-17 are ONLY eligible for Pfizer-BioNTech COVID-19 Vaccine
- Adolescents aged 18 years and older are eligible for all COVID-19 vaccines

**Persons vaccinated outside the United States**

- Received all recommended doses of an FDA-authorized COVID-19 vaccine, do not need additional doses
- Received a non FDA-authorized vaccine
  - If vaccine is listed for emergency use by the World Health Organization (WHO) and received all recommended doses, do not need any additional doses with an FDA-authorized vaccine
  - If vaccine is listed for emergency use by WHO, but has not received all recommended doses, may be offered a complete FDA-authorized series
  - If vaccine is not listed for emergency use by WHO, may be offered a complete FDA-authorized COVID-19 vaccine series

**Contraindications**

- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine
- Immediate (within 4 hours of exposure) allergic reaction of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine

**Precaution**

- Immediate allergic reaction to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies (excluding subcutaneous immunotherapy for allergies, i.e., “allergy shots”)

**Post-vaccination observation periods**

- 30 minutes: persons with a precaution to vaccination (i.e., history of an immediate allergic reaction of any severity to a vaccine or injectable therapy) and persons with a history of anaphylaxis due to any cause
- 15 minutes: all other persons

**SARS-CoV-2 antibody testing**

- Antibody testing not recommended for vaccine decision-making or to assess immunity following vaccination

---

*Consider an additional dose at least 28 days after the initial 2-dose primary series for people with moderate to severe immune compromise.

†Although CDC provides considerations for a mixed series in exceptional circumstances, this is still considered an administration error that requires VAERS reporting.